公开(公告)号：WO2014182279A1

公开(公告)日：2014-11-13

申请号：PCT/US2013/039791

申请日：2013-05-07

Applicant: EUTHYMICS BIOSCIENCE, INC. ,  MCKINNEY, Anthony, Alexander ,  BYMASTER, Franklin, Porter

Inventor： MCKINNEY, Anthony, Alexander ,  BYMASTER, Franklin, Porter

IPC: A61K31/403

CPC classification number: A61K31/403 ,  A61K31/135 ,  A61K31/145 ,  A61K31/185 ,  A61K31/4178 ,  A61K31/485 ,  A61K31/519 ,  A61K2300/00

Abstract: The present invention relates to (+)-l -(3,4-dichlorophenyl )-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)- 1-(3,4- dichlorophenyl)-3-azabicyclo[3.1.OJhexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)- l-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (-)-enantiomer

Abstract translation: 本发明涉及（+） - 1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷及其药学上可接受的盐，其包含（+） - 1-（3,4-二氯苯基） 3-氮杂二环[3.1.0]己烷或其药学上可接受的盐，以及用于治疗或预防酒精相关或成瘾性障碍的方法。 （+） - 1-（3,4-二氯苯基）-3-氮杂双环[3.1.0]己烷或其药学上可接受的盐优选基本上不含相应的（ - ） - 对映异构体

公开(公告)号：WO2012177263A1

公开(公告)日：2012-12-27

申请号：PCT/US2011/041866

申请日：2011-06-24

Applicant: INTRA-CELLULAR THERAPIES, INC. ,  PENG, Youyi ,  WENNOGLE, Lawrence ,  ZHANG, Qiang ,  TOMESCH, John

Inventor： PENG, Youyi ,  WENNOGLE, Lawrence ,  ZHANG, Qiang ,  TOMESCH, John

IPC: A01N43/64 ,  A61K31/41 ,  A61K31/415

CPC classification number: C07D401/12 ,  A61K31/41 ,  A61K31/415 ,  A61K31/454 ,  A61K31/4745 ,  A61K31/506 ,  A61K31/7068 ,  A61K33/24 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function to effect the activity of certain acetylcholine receptors and subtypes therein.

Abstract translation: 本发明涉及与烟碱受体拮抗剂有关的化合物和治疗方法。 例如，化合物和治疗方法起到影响其中某些乙酰胆碱受体和亚型的活性的作用。

公开(公告)号：WO2017116465A1

公开(公告)日：2017-07-06

申请号：PCT/US2015/068279

申请日：2015-12-31

Applicant: COLGATE-PALMOLIVE COMPANY

Inventor： NABI, Zeenat ,  CHENG, Shujiang ,  SIOMYK, Halyna ,  DU-THUMM, Laurence, D.

IPC: A61Q17/00 ,  A61Q19/00 ,  A61K8/44 ,  A61K8/46 ,  A61K8/02 ,  A61K8/04

CPC classification number: A61Q19/00 ,  A61K8/0216 ,  A61K8/042 ,  A61K8/44 ,  A61K8/466 ,  A61Q17/00

Abstract: Described herein, are personal care compositions comprising taurine in combination with arginine and glycine, and methods for using the compositions to effect reduction of skin irritation and or inflammation, and/or improving barrier repair of the skin.

Abstract translation: 本文描述了包含牛磺酸与精氨酸和甘氨酸组合的个人护理组合物，以及使用所述组合物来减少皮肤刺激和/或炎症和/或改善皮肤的屏障修复的方法。

公开(公告)号：WO2017116444A1

公开(公告)日：2017-07-06

申请号：PCT/US2015/068157

申请日：2015-12-30

Applicant: COLGATE-PALMOLIVE COMPANY

Inventor： HINRICHS, Ruth ,  BRUNELLA, Andre ,  MATUR, Turan

IPC: A61Q11/00 ,  A01N31/02 ,  A01N31/08 ,  A01N59/16

CPC classification number: A01N31/02 ,  A01N59/16 ,  A61K8/34 ,  A61K8/345 ,  A61K8/37 ,  A61Q11/00 ,  A01N31/04 ,  A01N37/40

Abstract: This invention relates to a dentifrice comprising (i) at least one source of ionic tin; and (ii) an antibacterial system comprising caprylyl glycol together with 3-phenyl-1-propanol, phenethyl salicylate, or both 3-phenyl-1-propanol and phenethyl salicylate, as well as to methods of using and of making these compositions.

Abstract translation: 本发明涉及一种洁齿剂，其包含（i）至少一种离子锡源; 和（ii）包含辛基乙二醇连同3-苯基-1-丙醇，水杨酸苯乙酯或3-苯基-1-丙醇和水杨酸苯乙酯二者的抗菌体系，以及使用和制备这些组合物的方法。 / p>

公开(公告)号：WO2010141085A1

公开(公告)日：2010-12-09

申请号：PCT/US2010/001611

申请日：2010-06-02

Applicant: BIORELIX PHARMACEUTICALS, INC. ,  MYUNG, Jayhyuk ,  BLOUNT, Kenneth, F. ,  FORBES, Christen, Douglas ,  OSTERMAN, David

Inventor： MYUNG, Jayhyuk ,  BLOUNT, Kenneth, F. ,  FORBES, Christen, Douglas ,  OSTERMAN, David

IPC: C12Q1/68

CPC classification number: C12N15/111 ,  C12N2310/16 ,  C12N2320/10

Abstract: Methods, compositions and assays that measure the effect of a test compound on induction of ligand-induced ribowitch-mediated transcription termination are disclosed. The methods and the assays are useful in identifying drug candidates that modulate transcription by binding to a riboswitch, for example.

Abstract translation: 公开了测量化合物对诱导配体诱导的核糖核酸转录终止诱导作用的方法，组合物和测定方法。 方法和测定法可用于鉴定例如通过结合核糖开关调节转录的候选药物。

公开(公告)号：WO2010019208A1

公开(公告)日：2010-02-18

申请号：PCT/US2009/004576

申请日：2009-08-11

Applicant: BIORELIX PHARMACEUTICALS, INC. ,  DIXON, Brian, R. ,  BLOUNT, Kenneth, F. ,  BERMAN, Judd ,  COISH, Philip, D.G. ,  OSTERMAN, David ,  BERMAN, Judd ,  HARPREET, Kaur ,  KELLS, Kevin ,  WICKENS, Phil ,  WILSON, Jeffrey ,  WU, Justin

Inventor： DIXON, Brian, R. ,  BLOUNT, Kenneth, F. ,  BERMAN, Judd ,  COISH, Philip, D.G. ,  OSTERMAN, David ,  BERMAN, Judd ,  HARPREET, Kaur ,  KELLS, Kevin ,  WICKENS, Phil ,  WILSON, Jeffrey ,  WU, Justin

IPC: A01N43/60 ,  A61K31/495 ,  A61K31/505

CPC classification number: A61K31/495 ,  A61K31/505 ,  C07D475/02 ,  Y02A50/401 ,  Y02A50/471 ,  Y02A50/473 ,  Y02A50/481

Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.

Abstract translation: 本发明涉及新的黄素衍生物和其它黄素衍生物，其用途和用作核糖开关配体和/或抗感染剂的组合物。 本发明还提供了制备新型黄素衍生物的方法。

公开(公告)号：WO2009032308A8

公开(公告)日：2009-03-12

申请号：PCT/US2008/010426

申请日：2008-09-05

Applicant: REGENTS OF THE UNIVERSITY OF COLORADO ,  BATEY, Robert, T. ,  GILBERT, Sunny

Inventor： BATEY, Robert, T. ,  GILBERT, Sunny

IPC: A61K48/00 ,  A61P43/00 ,  C07H21/04 ,  C12N15/87

Abstract: Embodiments of the present invention provide for SAM-II riboswitches and analogs thereof, and methods for using the same. In certain embodiments of the present invention, test compounds are identified that associate with SAM-II riboswitches. In other embodiments, test compounds found to associate with SAM II can be used to increase or decrease gene expression of Gram-negative bacterial organisms.

公开(公告)号：WO2023049356A1

公开(公告)日：2023-03-30

申请号：PCT/US2022/044549

申请日：2022-09-23

Applicant: COLGATE-PALMOLIVE COMPANY

Inventor： DAEP, Carlo ,  AHMED, Rabab

IPC: A61Q11/00 ,  A61K8/43 ,  A61K8/21

Abstract: The disclosure relates to oral care compositions comprising guanidine in free or orally acceptable salt form, a cationic quaternary ammonium compound (e.g., a pyridinium compound) (e.g., cetyl pyridinium chloride (CPC)), a fluoride source, and optionally a zinc source (e.g., zinc lactate or zinc citrate and zinc oxide) as well as to methods of using and of making these compositions.

公开(公告)号：WO2010110838A2

公开(公告)日：2010-09-30

申请号：PCT/US2010/000666

申请日：2010-03-04

Applicant: VET THERAPEUTICS INC. ,  HANSEN, Genevieve

Inventor： HANSEN, Genevieve

IPC: A61K39/395

CPC classification number: C07K16/464 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/20 ,  C07K2317/52 ,  C07K2317/732 ,  C07K2317/734 ,  G01N33/6854

Abstract: The invention provides recombinant protein (e.g., a recombinant antibody or soluble receptor) having (i) a binding domain capable of specific binding to an epitope (for example an antibody variable domains, a receptor, a growth factor, a cytokine, or a fragment of any of the foregoing which is capable of specifically binding the desired epitope) and (ii) an effector domain comprising a constant domain region which is derived from immunoglobulin of a first species which is a companion mammal, e.g. dog, cat, or horse, having engineered substitutions at one or more positions and having an altered interaction with one or more FcRs or other ligands, and optionally enhanced effector function, relative to the parent constant domain region.

Abstract translation: 本发明提供重组蛋白（例如，重组抗体或可溶性受体），其具有（i）能够与表位特异性结合的结合结构域（例如抗体可变结构域，受体，生长因子，细胞因子或片段 能够特异性结合所需表位的任何前述物质）和（ii）包含源自免疫球蛋白的恒定结构域区域的效应结构域，所述第一物种是伴侣哺乳动物，例如 狗，猫或马，在一个或多个位置具有改造的取代并且与一个或多个FcR或其它配体具有改变的相互作用，以及相对于母体恒定域区域可选地增强的效应子功能。

公开(公告)号：WO2023049279A1

公开(公告)日：2023-03-30

申请号：PCT/US2022/044412

申请日：2022-09-22

Applicant: COLGATE-PALMOLIVE COMPANY

Inventor： DAEP, Carlo ,  MYERS, Carl ,  GOVINDARAJU, Gokul ,  RAJAH, Divino

IPC: A61K8/19 ,  A61K8/21 ,  A61K8/24 ,  A61K8/43 ,  A61P1/02 ,  A61Q11/00

Abstract: The disclosure relates to oral care compositions comprising guanidine in free or orally acceptable salt form and a stannous ion source (e.g., stannous fluoride) as well as to methods of using and of making these compositions.